PresseBox
Pressemitteilung BoxID: 595317 (4SC AG)
  • 4SC AG
  • Fraunhoferstr. 22
  • 82152 Planegg-Martinsried
  • http://www.4sc.de
  • Ansprechpartner
  • Chad Rubin
  • +1 (646) 378-2947

4SC to host conference call on 14 May 2013 to present first quarter results of 2013

(PresseBox) (Planegg-Martinsried, ) 4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for cancer and autoimmune diseases, will announce first quarter results 2013 of the 4SC Group and publish the company's report on the first three months of 2013 on 14 May 2013. On this day the Management Board of 4SC AG will host a conference call at 3pm CEST (9am EDT) to inform about the consolidated financial statements and important developments in the reporting period and beyond.

Investors, financial analysts, and journalists participating in the conference call can access via the following telephone numbers:

Date: 14 May 2013
Time: 3pm CEST (9am EDT)
Dial-in numbers: +49-6958-999-0805 (Germany)
+44-207-153-2027 (UK)
+1-480-629-9726 (USA)
+49-6958-999-0805 (other countries)

Conference-ID: 4618702

After the conference call a replay will be available in the section 'Investors' / 'Events & Presentations' / 'Conference Calls & Webcasts' of the website www.4sc.com.

Legal Note

This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.

4SC AG

The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops targeted, small-molecule drugs for treating diseases with high unmet medical needs in various autoimmune and cancer indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies. Founded in 1997, 4SC had 86 employees at 31 March 2013. 4SC AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.